NEW YORK, Dec. 31, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Edison International (NYSE: EIX) Class Period: February 23, 2016 to November 12, 2018 Lead Plaintiff Deadline: January 15, 2019
During the class period, Edison International allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company failed to maintain electricity transmission and distribution networks in compliance with safety requirements and regulations promulgated under state law; (ii) consequently, the Company was in violation of state law and regulations; (iii) the Company’s noncompliant electricity networks created a significantly heightened risk of wildfires in California; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Get additional information about the EIX lawsuit: http://www.kleinstocklaw.com/pslra-1/edison-i...orm?wire=3
Altice USA, Inc. (NYSE: ATUS) Class Period: Pursuant and/or traceable to the June 2017 Initial Public Offering Lead Plaintiff Deadline: January 18, 2019
The complaint alleges that the Offering Documents issued pursuant to the IPO failed to disclose and/or misstated material information, including that: (1) “The Altice Way” proprietary growth model previously developed in Europe and described in the Offering Documents as a means to achieve superior margin performance was falsely touting Altice’s capacity to face already existing highly competitive environments and ever-changing consumer behaviors; (2) Altice was suffering from aggressively growing competition both in Europe and the United States, directly causing negative and decelerating revenue and EBITDA growth and impacting Altice’s market share; (3) specifically, Altice was suffering from mismanaged rate events, regulatory compliance and poorly managed network and customer care both in its France and Portugal segments, thereby impacting its customer base and churn rate; (4) Altice USA could not simply replicate the “The Altice Way” in the U.S.; and (5) as a result, Altice USA’s Offering Documents were materially misleading at all relevant times.
Get additional information about the ATUS lawsuit: http://www.kleinstocklaw.com/pslra-1/altice-u...orm?wire=3
Ternium S.A. (NYSE: TX) Class Period: May 1, 2014 to November 27, 2018 Lead Plaintiff Deadline: January 28, 2019
The complaint alleges that during the class period Ternium S.A. made materially false and/or misleading statements and/or failed to disclose that: (1) Defendant Paolo Rocca, Ternium’s Chairman, knew that one of his company’s executives paid cash to government officials from 2009 to 2012 to expedite compensation payments for the sale of Ternium’s Sidor unit; (2) this conduct would lead Rocca to be charged in a graft scheme and subject Ternium, its affiliates, and/or its executives to heightened governmental scrutiny; and (3) as a result, Ternium’s public statements were materially false and/or misleading at all relevant times. On November 27, 2018, Bloomberg reported that Rocca was indicted for his role in a graft scheme. According to the article, “The judge charged Rocca after the Argentine billionaire testified that one of his company’s executives paid an undisclosed amount of cash to government officials in monthly installments from 2009 to 2012. The officials were allegedly working for then-President Cristina Fernandez de Kirchner’s administration to speed up a compensation payment from Venezuela’s Hugo Chavez for the nationalization of Sidor, a unit that had been seized by Venezuela. Rocca’s group was compensated with $1.95 billion for the unit.”
Get additional information about the TX lawsuit: http://www.kleinstocklaw.com/pslra-1/ternium-...orm?wire=3
Allergan plc (NYSE: AGN) Class Period: May 9, 2017 to December 19, 2018 Lead Plaintiff Deadline: February 19, 2019
During the Class Period, and unbeknownst to investors, Allergan misled investors regarding various “pharma and device approvals” and concealed the fact that the Company’s CE Mark for its textured breast implants and tissue expanders was expiring in Europe. On December 19, 2018, the Company announced that, following a compulsory recall request from Agence Nationale de Sécurité du Médicament (“ANSM”), the French regulatory authority, the Company had suspended the sale of these products and that it was withdrawing all remaining supplies from European markets. The suspension of sales stemmed directly from the expiration of the company's CE Mark for these products, and the stock price fell drastically following the news.
Get additional information about the AGN lawsuit: http://www.kleinstocklaw.com/pslra-1/allergan...orm?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: J. Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
